Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an a...
Yan-Ruide Li, Yi-Chen Zhu, Yan-Qi Yu et al.· Cancer immunology research· 0 citations
Innate T cells, including invariant natural killer T (iNKT) cells, mucosal-associated invariant T (MAIT) cells, and γδ T cells, bridge innate and adaptive immunity through rapid responses to nonpeptide antigens, metabolites, and stress-associated signals. In cancer, these populations can promote tumor surveillance thro...
Yu-Ning Chen, Annabel S. Zhao, Catherine Zhang et al.· Annual Review of Cancer Biol...· 0 citations
HSPC-derived AlloESO-T cells are established as an off-the-shelf, mono-specific cytotoxic T cell therapy with scalable manufacturing, enhanced efficacy, and improved safety, which support broad applicability of AlloESO-T cells across solid tumors.
Yi-Chen Zhu, Jia-Ji Yu, Y. J. Kim et al.· Cell Reports Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.